Enjoy complimentary customisation on priority with our Enterprise License!
According to Technavio’s market research report, the regenerative medicine market in the US will grow rapidly at a CAGR of close to 24% during the forecast period. The increasing governmental funding in regenerative medicines is one of the key drivers that will stimulate growth in the market from 2017 to 2021. Governmental organizations are supporting the research and clinical trials of regenerative medicines due to the growing importance of regenerative medicines and the inability of research institutes and small companies to afford the research and developmental activities. In the US, most of the funds are provided by the National Institute of Health (NIH) and California Institute of Regenerative Medicine (CIRM) to conduct stem cell research. At present, the NIH is studying the disease mechanism using the induced pluripotent stem cells (iPSc) technology.
The growing focus on gene therapy is one of the key trends that will be witnessed in the regenerative medicine market in the US during the projected period. Researchers in the US are conducting gene therapy clinical trials to develop cancer therapy for hemophilia and thalassemia. The approval of gene therapy products in region such as EMEA and APAC will have a positive impact on the development of regenerative therapy.
The regenerative medicine market in the US is highly competitive and fragmented due to the presence of a number of large, medium, and small-sized companies. These vendors are increasingly competing against each other based on factors such as aggressive pricing, product differentiation, capital support for product upgrading, and distribution partnerships.
Key vendors in this market are -
Other prominent vendors in the market include ACE Surgical Supply, Acera Surgical, Acologix, Advanced Biologics, AlloCure, AlloSource, Alphatec Spine, ANTEROGEN, Antibe Therapeutics, Astellas Pharma, Athersys, Avita Medical, AxoGen, Bacterin International, Baxter, Bellicum Pharmaceuticals, BioCardia, Biogen, BioRestorative Therapies, Biostage, Bio-Tissue, BioTissue, bluebird bio, BONESUPPORT, BrainStorm Cell Therapeutics, Caladrius, Calimmune, Capricor Therapeutics, CELGENE, Cell Medica, Cell Therapy, CellBioMed, CellSeed, Celyad, CESCA THERAPEUTICS, CTM CRC, CryoLife, Cynata, Cytori Therapeutics, Dendreon Pharmaceuticals, DiscGenics, Fate Therapeutics, Fibrocell Science, Forticell Bioscience, Fortress Biotech, FUJIFILM Holdings, Gamida Cell, Geron, GlaxoSmithKline, Healthpoint, Histogen, Histogenics, Holostem Terapie Avanzate, Humacyte, Immunocellular Therapeutics, Integra LifeSciences, Intercytex, InVivo Therapeutics, iSTO Biologics, Janssen Pharmaceuticals, Juno Therapeutics, Juventas Therapeutics, Kiadis Pharma, LifeCell, LifeNet Health, Living Cell Technologies, Lonza, MaxCyte, MEDIPOST, Mesoblast, Nanofiber Solutions, Nanotope, Neuralstem, NewLink Genetics, Northwest Biotherapeutics, NovaRx, Opexa Therapeutics, ORGANOVO HOLDINGS, Orteq, Orthofix Holdings, Osiris Therapeutics, Pfizer, PHARMICELL, Pluristem, Prima BioMed, Q Therapeutics, Regenerex, Regenerys, Regience, Regrow, RENOVA THERAPEUTICS, RepliCel, ReproCELL, RhinoCyte, Rohto Pharma, RTI Surgical, SanBio, Sangamo Therapeutics, Shanghai Sunway Biotech, Shire, Stratatech, SURGILOGIX, Synergistic Technologies, TAKARA BIO, tella, Tissue Genesis, TissueGene, Txcell, VentriNova, Vericel, ViaCyte, and VistaGen Therapeutics.
Cell therapy is gaining momentum in the US due to its application in dermatology and cancer therapy. Also, various institutes and research laboratories in the US are increasingly focusing on the development of regenerative medicine by conducting studies on biological products that can be used for cell therapy. This will drive the demand for cell therapy products in the US in the forthcoming years.
The patient pool highly prefers hospitals over other health care centers because they are partnering with regenerative medicine manufacturing companies. This enables hospitals to provide cell therapy and tissue scaffolds to improve patient care and treatment. The rising number of wound treatment, craniomaxillofacial surgery, knee replacement cases, and soft tissue repair will also boost the influx of patients in hospitals.
Technavio also offers customization on reports based on specific client requirement
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Pipeline portfolio
PART 07: Market segmentation by product
PART 08: Market segmentation by application
PART 09: Market segmentation by end-user
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.